Subsequently, the PRJEB25780 cohort, comprising of 45 individuals diagnosed with advanced stomach cancer receiving PD-L1 inhibitor therapy, was employed to determine the effectiveness of the risk signature associated with calcium extrusion in accurately predicting the outcomes of immunotherapy. The gene discussed is CD274; the disease is gastric cancer.